

- [54] METHOD AND COMPOSITION FOR REDUCING WEIGHT
- [76] Inventor: Howard M. Pack, 12 Herkimer Rd., Scarsdale, N.Y. 10583
- [21] Appl. No.: 347,492
- [22] Filed: Feb. 10, 1982
- [51] Int. Cl.³ A61K 27/00
- [52] U.S. Cl. 424/248.57
- [58] Field of Search 424/248.57

References Cited

U.S. PATENT DOCUMENTS

3,491,093	1/1970	Pachter et al.	424/248.57
3,795,739	3/1974	Birkmayer et al.	424/274
3,939,253	2/1976	Bodor et al.	424/309
4,035,507	7/1977	Bodor et al.	424/311

OTHER PUBLICATIONS

- Chem. Abst. 82, 25910(c) (1975), Shibiaya.
- Chem. Abst. 86, 25944(z) (1977), Moore et al.
- Rivera-Calimlim et al. "Morphologic and Biochemical Changes in the Gut after Chronic Treatment with

L-Dopa" *J. of Pharm. & Exp. Therapeutics*, 184:2 (1973), pp. 440-448.

Gardos et al. "Weight Reduction in Schizophrenics by Molindone" *Amer. J. Psychiatry* 143: Mar. 3, 1977, pp. 302-304.

Primary Examiner—Douglas W. Robinson
Attorney, Agent, or Firm—Fitch, Even, Tabin & Flannery

[57] ABSTRACT

A method for reducing weight by the administration of L-Dopa or a stabilized form thereof with or without a decarboxylase inhibitor and Molindone wherein Molindone acts as a potentiator to enhance the weight reducing potency of L-Dopa in warm-blooded animals. The synergistic effect of the combination of L-Dopa and Molindone reduces the required dosage of the two drugs to levels which can be tolerated by higher forms of mammals, whereas individually the dosages required to reduce weight in higher mammals is not easily tolerated and may be toxic or lead to undesirable side effects.

8 Claims, No Drawings